首页 > 最新文献

Alcohol最新文献

英文 中文
30. Alcohol suppresses Kupffer cell maturation in a mouse model of high fat diet and alcohol-induced steatohepatitis 30.在高脂肪饮食和酒精诱导的脂肪性肝炎小鼠模型中,酒精抑制Kupffer细胞成熟
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-21 DOI: 10.1016/j.alcohol.2023.10.035
Steven A. Weinman, Sheetalnath Rooge, Isabel Aranzazu Pulido-Ruiz, Kyo Sasaki, Kyle Yuquimpo, Heer Mehta, Sumedha Gunewardena
{"title":"30. Alcohol suppresses Kupffer cell maturation in a mouse model of high fat diet and alcohol-induced steatohepatitis","authors":"Steven A. Weinman, Sheetalnath Rooge, Isabel Aranzazu Pulido-Ruiz, Kyo Sasaki, Kyle Yuquimpo, Heer Mehta, Sumedha Gunewardena","doi":"10.1016/j.alcohol.2023.10.035","DOIUrl":"https://doi.org/10.1016/j.alcohol.2023.10.035","url":null,"abstract":"","PeriodicalId":7712,"journal":{"name":"Alcohol","volume":"113 ","pages":"Pages 65-66"},"PeriodicalIF":2.3,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138336670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
31. The alcohol exposome- Impact on lung cilia function 31. 酒精暴露-对肺纤毛功能的影响
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-21 DOI: 10.1016/j.alcohol.2023.10.036
Todd A. Wyatt, Daren L. Knoell, Derrick R. Samuelson
{"title":"31. The alcohol exposome- Impact on lung cilia function","authors":"Todd A. Wyatt, Daren L. Knoell, Derrick R. Samuelson","doi":"10.1016/j.alcohol.2023.10.036","DOIUrl":"https://doi.org/10.1016/j.alcohol.2023.10.036","url":null,"abstract":"","PeriodicalId":7712,"journal":{"name":"Alcohol","volume":"113 ","pages":"Page 66"},"PeriodicalIF":2.3,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138346349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
19. Fecal microbiome transfer from moderate-dose alcohol-fed mice modulates gut-brain axis and ameliorates neuroinflammation in a sex-specific pattern 19. 中等剂量酒精喂养小鼠的粪便微生物组转移以性别特异性模式调节肠-脑轴并改善神经炎症
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-21 DOI: 10.1016/j.alcohol.2023.10.024
Adriana Souto Pereira Nuncio, Blaine Caslin, Cole Maguire, Cara Fonken, Esther Melamed
{"title":"19. Fecal microbiome transfer from moderate-dose alcohol-fed mice modulates gut-brain axis and ameliorates neuroinflammation in a sex-specific pattern","authors":"Adriana Souto Pereira Nuncio, Blaine Caslin, Cole Maguire, Cara Fonken, Esther Melamed","doi":"10.1016/j.alcohol.2023.10.024","DOIUrl":"https://doi.org/10.1016/j.alcohol.2023.10.024","url":null,"abstract":"","PeriodicalId":7712,"journal":{"name":"Alcohol","volume":"113 ","pages":"Page 62"},"PeriodicalIF":2.3,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138396003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
21. Hepatic stellate cells and alcohol: Investigating canonical Wnt/b-catenin signaling in models of alcohol-associated liver disease 21. 肝星状细胞与酒精:研究酒精相关肝病模型中的典型Wnt/b-连环蛋白信号
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-21 DOI: 10.1016/j.alcohol.2023.10.026
Lauren Rutt, Rebecca McCullough
{"title":"21. Hepatic stellate cells and alcohol: Investigating canonical Wnt/b-catenin signaling in models of alcohol-associated liver disease","authors":"Lauren Rutt, Rebecca McCullough","doi":"10.1016/j.alcohol.2023.10.026","DOIUrl":"https://doi.org/10.1016/j.alcohol.2023.10.026","url":null,"abstract":"","PeriodicalId":7712,"journal":{"name":"Alcohol","volume":"113 ","pages":"Page 63"},"PeriodicalIF":2.3,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138335296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
23. Ceramide as a novel link between alcohol use disorder and pulmonary inflammation 23. 神经酰胺作为酒精使用障碍和肺部炎症之间的新联系
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-21 DOI: 10.1016/j.alcohol.2023.10.028
Jamie L. Sturgill, Ilhem Messaoudi
{"title":"23. Ceramide as a novel link between alcohol use disorder and pulmonary inflammation","authors":"Jamie L. Sturgill, Ilhem Messaoudi","doi":"10.1016/j.alcohol.2023.10.028","DOIUrl":"https://doi.org/10.1016/j.alcohol.2023.10.028","url":null,"abstract":"","PeriodicalId":7712,"journal":{"name":"Alcohol","volume":"113 ","pages":"Pages 63-64"},"PeriodicalIF":2.3,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138345318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
24. Hepatic stellate cell-intrinsic role for IRF3 in TGFβ-induced fibrogenesis 24. IRF3在tgf β诱导的肝星状细胞纤维化中的内在作用
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-21 DOI: 10.1016/j.alcohol.2023.10.029
Jared B. Travers, Jianguo Wu, Christina K. Cajigas-Du Ross, Laura E. Nagy
{"title":"24. Hepatic stellate cell-intrinsic role for IRF3 in TGFβ-induced fibrogenesis","authors":"Jared B. Travers, Jianguo Wu, Christina K. Cajigas-Du Ross, Laura E. Nagy","doi":"10.1016/j.alcohol.2023.10.029","DOIUrl":"https://doi.org/10.1016/j.alcohol.2023.10.029","url":null,"abstract":"","PeriodicalId":7712,"journal":{"name":"Alcohol","volume":"113 ","pages":"Page 64"},"PeriodicalIF":2.3,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138345319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
10. SARS-CoV-2 immune responses in the lung are compromised by chronic alcohol consumption 10. 肺部的SARS-CoV-2免疫反应会因长期饮酒而受损
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-21 DOI: 10.1016/j.alcohol.2023.10.015
Sloan A. Lewis , Isaac R. Cinco , Brianna M. Doratt , Madison B. Blanton , Cherise Hoagland , Natali Newman , Michael Davies , Kathleen A. Grant , Ilhem Messaoudi
{"title":"10. SARS-CoV-2 immune responses in the lung are compromised by chronic alcohol consumption","authors":"Sloan A. Lewis , Isaac R. Cinco , Brianna M. Doratt , Madison B. Blanton , Cherise Hoagland , Natali Newman , Michael Davies , Kathleen A. Grant , Ilhem Messaoudi","doi":"10.1016/j.alcohol.2023.10.015","DOIUrl":"https://doi.org/10.1016/j.alcohol.2023.10.015","url":null,"abstract":"","PeriodicalId":7712,"journal":{"name":"Alcohol","volume":"113 ","pages":"Page 60"},"PeriodicalIF":2.3,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138356166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thiamine utilization and the lack of prescribing standardization: A critical examination “硫胺素的使用与处方规范的缺失:一个关键的审查”。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-17 DOI: 10.1016/j.alcohol.2023.10.041
Todd N. Brothers , Margaret Furtado , Mohammad A. Al-Mamun

Objectives

Thiamine is often prescribed for thiamine deficiency during hospitalization despite the lack of US-based clinical guidelines. This study aims to evaluate thiamine prescribing patterns and key characteristics associated with the deficiency to address gaps in care.

Methods

Data were obtained from electronic health records of hospitalized patients between September 1, 2021, and March 30, 2022. Alcohol use disorder (AUD) was defined by a positive Clinical Institute Withdrawal Assessment score or a positive serum alcohol level upon admission. Geriatric patients were defined as age ≥65. Cohort 1 was defined as: AUD, albumin <4 g/L, INR >1.5, and total bilirubin >3 mg/dL. Cohort 2 was defined as: age >65, albumin <4 g/L, hemoglobin <15 g/dL, and folate <4 ng/mL. A multivariable LASSO regression model was used to identify characteristics associated with higher thiamine dosing (>100 mg/day).

Results

Among 780 patients, 520 (66.7%) were identified as AUD, of which 265 (50.1%) were between the ages of 45–64 years. The AUD cohort was significantly different (p < 0.05) in the mean serum albumin 4.16 g/L (IQR: 3.8–4.5), AST 73.55 U/L (23.75–82.00), ALT 52.57 U/L (17.00–57.00), total bilirubin 0.98 (0.3–1.0), and INR 1.1 (0.99–1.12), compared to non-AUD patients with a mean serum albumin 3.75 g/L (3.3–4.2), AST 35.07 U/L (11.00–42.00), ALT 32.77 U/L (5.00–34.00), total bilirubin 0.89 (0.2–0.9), and INR 1.21 (1.0–1.22). In the geriatric cohort, 136 patients (17%) had a mean serum albumin 3.77 g/L (3.4–4.2), AST 38.66 U/L (14.0–41.0), ALT 29.36 U/L (9.0–37.0), total bilirubin 0.62 mg/dL (0.30–0.90), and direct bilirubin 0.12 mg/dL (0.00–0.20), compared to the non-geriatric cohort with a mean serum albumin 4.10 g/L (3.8–4.40), AST 66.44 U/L (21.0–75.0), ALT 50.03 U/L (16.00–53.75), total bilirubin 1.02 mg/dL (0.30–1.00), and direct bilirubin 0.31 mg/dL (0.00–0.20). In cohort 1, 40.6% patients were between 51 and 64 years old, (66.5%) male, and had a BMI <25 (36.4%). In cohort 2, 52.6% were between 65 and 70 years old, (57.9%) male, and had a BMI <25 (57.9%). Cohort 1 were prescribed a dose of 100 mg (47.7 %), oral (63.5%), intramuscular (18.2%), daily (58.9%), one-day duration (49.4%) most frequently. Cohort 2 were prescribed a dose of 100 mg (56.0%), oral (77.2%), daily (77.2%), one-day duration (29.8%) most frequently. The AUD was significantly associated with having a higher dosage (e.g., >100 mg) of thiamine prescribed per day OR 1.62 (1.11–2.37) (p < 0.01).

Conclusions

This study confirms that thiamine prescribing patterns vary during hospitalization and suggest specific laboratory findings may aid in identifying cohorts associated with the deficiency.

目的:尽管缺乏美国临床指南,但在住院期间经常为硫胺素缺乏症开硫胺素处方。本研究旨在评估与缺乏相关的硫胺素处方模式和关键特征,以解决护理差距。方法:数据来源于2021年9月1日至2022年3月30日住院患者的电子健康记录。酒精使用障碍(AUD)的定义是临床研究所戒断评估评分阳性或入院时血清酒精水平阳性。老年患者被定义为年龄在50 - 65岁之间。队列1定义为:AUD,白蛋白< 4g/L, INR > 1.5,总胆红素> 3mg /dL。队列2定义为:年龄bb0 ~ 65岁,白蛋白< 4g/L,血红蛋白< 15g /dL,叶酸< 4ng/mL。使用多变量LASSO回归模型来确定高硫胺素剂量(100mg/天)的相关特征。结果:780例患者中,AUD 520例(66.7%),265例(50.1%),年龄在45-64岁之间。与平均血清白蛋白3.75g/L(3.3-4.2)、AST 35.07 U/L(11.00-42.00)、ALT 32.77 U/L(5.00-34.00)、总胆红素0.89(0.2-0.9)、INR 1.21(1.0-1.22)的非AUD患者相比,AUD组平均血清白蛋白4.16g/L (IQR: 3.8-4.5)、AST 73.55 U/L(23.75-82.00)、ALT 52.57 U/L(17.00-57.00)、总胆红素0.98(0.3-1.0)、INR 1.1(0.99-1.12)差异有统计学意义(p值< 0.05)。在老年队列中,136例(17%)患者的平均血清白蛋白为3.77g/L (3.4-4.2), AST为38.66 U/L(14.0-41.0), ALT为29.36 U/L(9.0-37.0),总胆红素为0.62mg/dL(0.30-0.90),直接胆红素为0.12 mg/dL(0.00-0.20),而非老年队列的平均血清白蛋白为4.10g/L (3.8-4.40), AST为66.44 U/L(21.0-75.0), ALT为50.03 U/L(16.00-53.75),总胆红素1.02mg/dL(0.30-1.00),直接胆红素为0.31 mg/dL(0.00-0.20)。在队列1中,40.6%的患者年龄在51-64岁之间,男性(66.5%),BMI < 25(36.4%)。队列2中,52.6%的患者年龄在65-70岁之间,男性(57.9%),BMI < 25(57.9%)。队列1的处方剂量为100mg(47.7%),口服(63.5%),肌肉注射(18.2%),每日(58.9%),1天疗程(49.4%)最常见。队列2最常见的是100mg(56.0%),口服(77.2%),每日(77.2%),1天疗程(29.8%)。AUD与每天服用较多的硫胺素(例如100毫克)或1.62(1.11-2.37)显著相关(p < 0.01)。结论:本研究证实,在住院期间,硫胺素的处方模式有所不同,并提示特定的实验室结果可能有助于确定与缺乏症相关的队列。
{"title":"Thiamine utilization and the lack of prescribing standardization: A critical examination","authors":"Todd N. Brothers ,&nbsp;Margaret Furtado ,&nbsp;Mohammad A. Al-Mamun","doi":"10.1016/j.alcohol.2023.10.041","DOIUrl":"10.1016/j.alcohol.2023.10.041","url":null,"abstract":"<div><h3>Objectives</h3><p>Thiamine is often prescribed for thiamine deficiency during hospitalization despite the lack of US-based clinical guidelines. This study aims to evaluate thiamine prescribing patterns and key characteristics associated with the deficiency to address gaps in care.</p></div><div><h3>Methods</h3><p>Data were obtained from electronic health records of hospitalized patients between September 1, 2021, and March 30, 2022. Alcohol use disorder (AUD) was defined by a positive Clinical Institute Withdrawal Assessment score or a positive serum alcohol level upon admission. Geriatric patients were defined as age ≥65. Cohort 1 was defined as: AUD, albumin &lt;4 g/L, INR &gt;1.5, and total bilirubin &gt;3 mg/dL. Cohort 2 was defined as: age &gt;65, albumin &lt;4 g/L, hemoglobin &lt;15 g/dL, and folate &lt;4 ng/mL. A multivariable LASSO regression model was used to identify characteristics associated with higher thiamine dosing (&gt;100 mg/day).</p></div><div><h3>Results</h3><p>Among 780 patients, 520 (66.7%) were identified as AUD, of which 265 (50.1%) were between the ages of 45–64 years. The AUD cohort was significantly different (<em>p</em> &lt; 0.05) in the mean serum albumin 4.16 g/L (IQR: 3.8–4.5), AST 73.55 U/L (23.75–82.00), ALT 52.57 U/L (17.00–57.00), total bilirubin 0.98 (0.3–1.0), and INR 1.1 (0.99–1.12), compared to non-AUD patients with a mean serum albumin 3.75 g/L (3.3–4.2), AST 35.07 U/L (11.00–42.00), ALT 32.77 U/L (5.00–34.00), total bilirubin 0.89 (0.2–0.9), and INR 1.21 (1.0–1.22). In the geriatric cohort, 136 patients (17%) had a mean serum albumin 3.77 g/L (3.4–4.2), AST 38.66 U/L (14.0–41.0), ALT 29.36 U/L (9.0–37.0), total bilirubin 0.62 mg/dL (0.30–0.90), and direct bilirubin 0.12 mg/dL (0.00–0.20), compared to the non-geriatric cohort with a mean serum albumin 4.10 g/L (3.8–4.40), AST 66.44 U/L (21.0–75.0), ALT 50.03 U/L (16.00–53.75), total bilirubin 1.02 mg/dL (0.30–1.00), and direct bilirubin 0.31 mg/dL (0.00–0.20). In cohort 1, 40.6% patients were between 51 and 64 years old, (66.5%) male, and had a BMI &lt;25 (36.4%). In cohort 2, 52.6% were between 65 and 70 years old, (57.9%) male, and had a BMI &lt;25 (57.9%). Cohort 1 were prescribed a dose of 100 mg (47.7 %), oral (63.5%), intramuscular (18.2%), daily (58.9%), one-day duration (49.4%) most frequently. Cohort 2 were prescribed a dose of 100 mg (56.0%), oral (77.2%), daily (77.2%), one-day duration (29.8%) most frequently. The AUD was significantly associated with having a higher dosage (e.g., &gt;100 mg) of thiamine prescribed per day OR 1.62 (1.11–2.37) (<em>p</em> &lt; 0.01).</p></div><div><h3>Conclusions</h3><p>This study confirms that thiamine prescribing patterns vary during hospitalization and suggest specific laboratory findings may aid in identifying cohorts associated with the deficiency.</p></div>","PeriodicalId":7712,"journal":{"name":"Alcohol","volume":"117 ","pages":"Pages 11-19"},"PeriodicalIF":2.3,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138049007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishing the safety of phenobarbital treatment of alcohol withdrawal syndrome on general medical wards: A retrospective cohort study 建立苯巴比妥治疗普通病房酒精戒断综合征的安全性:一项回顾性队列研究。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-17 DOI: 10.1016/j.alcohol.2023.10.005
Matthew V. Ronan , Rahul B. Ganatra , Jussi Saukkonen

Introduction

Concern about adverse effects from phenobarbital limits its use in treating alcohol withdrawal syndrome (AWS) on general medical wards. Benzodiazepines are the recommended treatment for inpatient management of AWS, yet a subset of patients have an inadequate response or experience complications of AWS despite treatment with benzodiazepines. Data supporting an alternative treatment are needed. We set out to estimate the rate of serious adverse events (SAEs) of phenobarbital treatment for AWS on general medical wards.

Methods

Retrospective cohort study of all general medical ward patients hospitalized at a single tertiary urban VA Medical Center from October 2018–May 2021 who received phenobarbital for treatment of AWS. Primary outcomes were SAEs attributed to phenobarbital and treatment failure. SAEs were defined as ICU transfer or intubation for over-sedation, pneumonia, and death. Treatment failure was defined as progression of withdrawal resulting in seizure, ICU transfer, behavioral emergencies, or death.

Results

During the study period, phenobarbital was administered in 29% (244) of all AWS hospitalizations. Among them, 93% had a history of AWS hospitalization and 68% had a history of complicated AWS. Fifty-three percent of patients met criteria for moderate, severe, or complicated withdrawal prior to phenobarbital initiation. The mean cumulative dose of phenobarbital per patient was 966.5 mg (13.6 mg/kg). SAEs occurred in 1 of 244 hospitalizations (0.4%): there were no intubations, ICU transfers for oversedation, or deaths due to phenobarbital or AWS. One case of pneumonia was possibly attributable to phenobarbital. Treatment failures (6 ICU transfers, 9 behavioral emergencies) were identified during 12 of 244 hospitalizations (4.9%).

Conclusions

SAEs and treatment failures were infrequent among 148 patients treated with phenobarbital across 244 hospitalizations with a mean cumulative dose of 966.5 mg per patient. Our findings suggest that phenobarbital is a safe alternative treatment of AWS in general medical ward patients.

简介:对苯巴比妥不良反应的担忧限制了其在普通病房治疗酒精戒断综合征(AWS)中的应用。苯二氮卓类药物是住院治疗AWS的推荐治疗方法,然而,尽管使用苯二氮卓类药物治疗,仍有一部分患者对AWS反应不足或出现并发症。需要支持替代治疗的数据。我们着手估计在普通病房接受苯巴比妥治疗的AWS患者严重不良事件(SAEs)的发生率。方法:回顾性队列研究2018年10月至2021年5月在单一三级城市VA医疗中心住院的所有普通病房患者,这些患者接受了苯巴比妥治疗AWS。主要结局是由苯巴比妥和治疗失败引起的急性脑梗死。sae被定义为因过度镇静、肺炎和死亡而转入ICU或插管。治疗失败的定义为停药进展导致癫痫发作、转入ICU、行为紧急或死亡。结果:在研究期间,29%(244)的AWS住院患者使用了苯巴比妥。其中93%有AWS住院史,68%有复杂AWS病史。53%的患者在苯巴比妥开始治疗前符合中度、重度或复杂戒断标准。每位患者苯巴比妥的平均累积剂量为966.5mg (13.6 mg/kg)。244例住院患者中有1例(0.4%)发生了急性呼吸窘迫事件:没有插管,没有因过度镇静而转移到ICU,也没有因苯巴比妥或AWS导致的死亡。1例肺炎可能归因于苯巴比妥。244例住院患者中有12例(4.9%)出现治疗失败(6例转至ICU, 9例行为紧急情况)。结论:在244例平均累积剂量为966.5mg /例的148例接受苯巴比妥治疗的住院患者中,SAEs和治疗失败罕见。我们的研究结果表明,苯巴比妥是普通病房患者的一种安全的替代治疗方法。
{"title":"Establishing the safety of phenobarbital treatment of alcohol withdrawal syndrome on general medical wards: A retrospective cohort study","authors":"Matthew V. Ronan ,&nbsp;Rahul B. Ganatra ,&nbsp;Jussi Saukkonen","doi":"10.1016/j.alcohol.2023.10.005","DOIUrl":"10.1016/j.alcohol.2023.10.005","url":null,"abstract":"<div><h3>Introduction</h3><p>Concern about adverse effects from phenobarbital limits its use in treating alcohol withdrawal syndrome (AWS) on general medical wards. Benzodiazepines are the recommended treatment for inpatient management of AWS, yet a subset of patients have an inadequate response or experience complications of AWS despite treatment with benzodiazepines. Data supporting an alternative treatment are needed. We set out to estimate the rate of serious adverse events (SAEs) of phenobarbital treatment for AWS on general medical wards.</p></div><div><h3>Methods</h3><p>Retrospective cohort study of all general medical ward patients hospitalized at a single tertiary urban VA Medical Center from October 2018–May 2021 who received phenobarbital for treatment of AWS. Primary outcomes were SAEs attributed to phenobarbital and treatment failure. SAEs were defined as ICU transfer or intubation for over-sedation, pneumonia, and death. Treatment failure was defined as progression of withdrawal resulting in seizure, ICU transfer, behavioral emergencies, or death.</p></div><div><h3>Results</h3><p>During the study period, phenobarbital was administered in 29% (244) of all AWS hospitalizations. Among them, 93% had a history of AWS hospitalization and 68% had a history of complicated AWS. Fifty-three percent of patients met criteria for moderate, severe, or complicated withdrawal prior to phenobarbital initiation. The mean cumulative dose of phenobarbital per patient was 966.5 mg (13.6 mg/kg). SAEs occurred in 1 of 244 hospitalizations (0.4%): there were no intubations, ICU transfers for oversedation, or deaths due to phenobarbital or AWS. One case of pneumonia was possibly attributable to phenobarbital. Treatment failures (6 ICU transfers, 9 behavioral emergencies) were identified during 12 of 244 hospitalizations (4.9%).</p></div><div><h3>Conclusions</h3><p>SAEs and treatment failures were infrequent among 148 patients treated with phenobarbital across 244 hospitalizations with a mean cumulative dose of 966.5 mg per patient. Our findings suggest that phenobarbital is a safe alternative treatment of AWS in general medical ward patients.</p></div>","PeriodicalId":7712,"journal":{"name":"Alcohol","volume":"116 ","pages":"Pages 29-34"},"PeriodicalIF":2.3,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138049008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of elevated blood alcohol concentrations in elderly patients following a ground level fall: A matched analysis from the national trauma quality program 老年患者地面坠落后血液酒精浓度升高的结果:来自国家创伤质量项目的匹配分析
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-13 DOI: 10.1016/j.alcohol.2023.11.004
Nasim Ahmed , Yen-Hong Kuo

Background

The rising elderly population and the concomitant increase in alcohol consumption can result in a ground level fall (GLF). The purpose of this study is to evaluate the in-hospital mortality, hospital length of stay, and discharge disposition of elderly patients who sustained a ground level fall (GLF) and tested positive for an elevated blood alcohol concentration (BAC).

Methods

The data of patients who were 65 years and older, had an injury after a GLF, and tested for BAC were accessed from the American College of Surgeon – Trauma Quality Improvement Program (ACS-TQIP) from the calendar years of 2011–2016. Patients’ demography, injury, comorbidities, and outcomes were compared between the groups who tested positive (>0.08 g/dL) and negative (0 mg/dL) for BAC. Univariate, followed by matched analyses were performed. All p values are two-sided, and a p value < 0.05 is considered statistically significant.

Results

Out of 20,163 patients who satisfied the inclusion criteria, 2398 patients (∼12%) tested positive for an elevated BAC. There were significant differences found between the two groups, BAC-positive vs. BAC-negative, in univariate analysis for age and sex with p values < 0.001. Propensity score matching balanced demographic characteristics; however, differences remained in certain comorbidities. Exact matching balanced patient demography, injury, and comorbidities. The paired-matched analysis showed no significant differences between the two groups for in-hospital mortality (2.1% vs. 2.1%, p = 1) and median hospital length of stay (5[4–5] vs. 5[5–5], p = 0.307). A higher proportion of patients in the BAC group suffered from alcohol withdrawal syndrome (AWS) and deep vein thrombosis (DVT) complications (9.5% vs. 1.4%, p < 0.001 and 1.5% vs. 0.5%, p = 0.018) compared to BAC-negative patients. A slightly higher percentage of patients in the BAC-positive group were discharged home without any additional services (39.6% vs. 36.9%, p = 0.009).

Conclusion

Of the elderly patients who sustained a GLF and tested for BAC, approximately 12% tested positive for BAC. The overall in-hospital mortality was 2.1%. The BAC-positive group suffered from higher complications of AWS and DVT, and more than 60% of patients required additional services at the time of discharge.

背景:老年人口的增加和伴随的酒精消费的增加可导致地面水平下降(GLF)。本研究的目的是评估持续地面坠落(GLF)且血液酒精浓度(BAC)升高呈阳性的老年患者的住院死亡率、住院时间和出院处理。方法:从2011-2016年美国外科医师学会创伤质量改善计划(ACS-TQIP)中获取65岁及以上、GLF后损伤并进行BAC检测的患者数据。比较BAC检测阳性(0.08g/dl)和阴性(0 mg/dl)两组患者的人口统计学、损伤、合并症和结果。单变量分析,随后进行匹配分析。结果:在20163例符合纳入标准的患者中,2398例(约12%)患者检测出BAC升高呈阳性。在年龄和性别的单变量分析中,BAC阳性和BAC阴性两组之间存在显著差异,P值为P值。结论:在持续GLF并进行BAC检测的老年患者中,约12%的患者BAC检测呈阳性。住院总死亡率为2.1%。bac阳性组有更高的AWS和DVT并发症,超过60%的患者在出院时需要额外的服务。
{"title":"Outcomes of elevated blood alcohol concentrations in elderly patients following a ground level fall: A matched analysis from the national trauma quality program","authors":"Nasim Ahmed ,&nbsp;Yen-Hong Kuo","doi":"10.1016/j.alcohol.2023.11.004","DOIUrl":"10.1016/j.alcohol.2023.11.004","url":null,"abstract":"<div><h3>Background</h3><p>The rising elderly population and the concomitant increase in alcohol consumption can result in a ground level fall (GLF). The purpose of this study is to evaluate the in-hospital mortality, hospital length of stay, and discharge disposition of elderly patients who sustained a ground level fall (GLF) and tested positive for an elevated blood alcohol concentration (BAC).</p></div><div><h3>Methods</h3><p>The data of patients who were 65 years and older, had an injury after a GLF, and tested for BAC were accessed from the American College of Surgeon – Trauma Quality Improvement Program (ACS-TQIP) from the calendar years of 2011–2016. Patients’ demography, injury, comorbidities, and outcomes were compared between the groups who tested positive (&gt;0.08 g/dL) and negative (0 mg/dL) for BAC. Univariate, followed by matched analyses were performed. All <em>p</em> values are two-sided, and a <em>p</em> value &lt; 0.05 is considered statistically significant.</p></div><div><h3>Results</h3><p>Out of 20,163 patients who satisfied the inclusion criteria, 2398 patients (∼12%) tested positive for an elevated BAC. There were significant differences found between the two groups, BAC-positive vs. BAC-negative, in univariate analysis for age and sex with <em>p</em> values &lt; 0.001. Propensity score matching balanced demographic characteristics; however, differences remained in certain comorbidities. Exact matching balanced patient demography, injury, and comorbidities. The paired-matched analysis showed no significant differences between the two groups for in-hospital mortality (2.1% vs. 2.1%, <em>p</em> = 1) and median hospital length of stay (5[4–5] vs. 5[5–5], <em>p</em> = 0.307). A higher proportion of patients in the BAC group suffered from alcohol withdrawal syndrome (AWS) and deep vein thrombosis (DVT) complications (9.5% vs. 1.4%, <em>p</em> &lt; 0.001 and 1.5% vs. 0.5%, <em>p</em> = 0.018) compared to BAC-negative patients. A slightly higher percentage of patients in the BAC-positive group were discharged home without any additional services (39.6% vs. 36.9%, <em>p</em> = 0.009).</p></div><div><h3>Conclusion</h3><p>Of the elderly patients who sustained a GLF and tested for BAC, approximately 12% tested positive for BAC. The overall in-hospital mortality was 2.1%. The BAC-positive group suffered from higher complications of AWS and DVT, and more than 60% of patients required additional services at the time of discharge.</p></div>","PeriodicalId":7712,"journal":{"name":"Alcohol","volume":"119 ","pages":"Pages 83-88"},"PeriodicalIF":2.5,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Alcohol
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1